PMID- 23894047
OWN - NLM
STAT- MEDLINE
DCOM- 20140317
LR  - 20211021
IS  - 1477-0962 (Electronic)
IS  - 0961-2033 (Print)
IS  - 0961-2033 (Linking)
VI  - 22
IP  - 9
DP  - 2013 Aug
TI  - Effects of rituximab-based B-cell depletion therapy on skin manifestations of 
      lupus erythematosus--report of 17 cases and review of the literature.
PG  - 932-9
LID - 10.1177/0961203313497115 [doi]
AB  - Cutaneous manifestations occur frequently in systemic lupus erythematosus (SLE) 
      and are pathognomonic in subacute-cutaneous lupus erythematosus (SCLE) and 
      chronic cutaneous lupus erythematosus (CCLE). Although B-cell depletion therapy 
      (BCDT) has demonstrated efficacy in SLE with visceral involvement, its usefulness 
      for patients with predominant skin manifestations has not been fully established. 
      In this single-centre, retrospective study 14 consecutive SLE, one CCLE and two 
      SCLE patients with recalcitrant skin involvement were treated with 2 x rituximab 
      1 g, and 1 x cyclophosphamide 750 mg. Six months after BCDT, nine of 17 (53%) 
      patients were in complete (CR) or partial remission (PR). Relapses occurred in 12 
      patients (71%) at a mean time of 10 +/- 1.8 months after BCDT. A second cycle of 
      BCDT achieved a more sustained remission in seven of nine patients (78%) lasting 
      for a mean time of 18.4 +/- 2.7 months. Minor adverse events were experienced by 
      three patients. Mean follow-up was 30 months. Our own results and the literature 
      review demonstrate that BCDT based on rituximab is well tolerated and may be 
      effective for cutaneous lesions of lupus erythematosus. Randomized controlled 
      trials are necessary to further evaluate the value of BCDT for this group of 
      patients.
FAU - Hofmann, S C
AU  - Hofmann SC
AD  - Centre for Rheumatology Research, University College London, London, UK. 
      silke.hofmann@helios-kliniken.de
FAU - Leandro, M J
AU  - Leandro MJ
FAU - Morris, S D
AU  - Morris SD
FAU - Isenberg, D A
AU  - Isenberg DA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Immunologic Factors)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal, Murine-Derived/adverse effects/*therapeutic use
MH  - B-Lymphocytes/*immunology
MH  - Cohort Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunologic Factors/adverse effects/therapeutic use
MH  - Lupus Erythematosus, Cutaneous/*drug therapy/immunology
MH  - Lupus Erythematosus, Systemic/*drug therapy/immunology
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Retrospective Studies
MH  - Rituximab
PMC - PMC4107853
OTO - NOTNLM
OT  - Cutaneous lupus
OT  - discoid lupus
OT  - subacute lupus erythematosus
OT  - systemic lupus erythematosus
EDAT- 2013/07/31 06:00
MHDA- 2014/03/19 06:00
PMCR- 2014/07/23
CRDT- 2013/07/30 06:00
PHST- 2013/07/30 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2014/03/19 06:00 [medline]
PHST- 2014/07/23 00:00 [pmc-release]
AID - 22/9/932 [pii]
AID - 10.1177_0961203313497115 [pii]
AID - 10.1177/0961203313497115 [doi]
PST - ppublish
SO  - Lupus. 2013 Aug;22(9):932-9. doi: 10.1177/0961203313497115.